CRSP - CRISPR Therapeutics Quick Ratio

CRISPR Therapeutics AG (CRSP) relies on a diversified network of laboratories to ensure the stable transport of complex biomaterials. Strict liquidity clearly demonstrates the company's solvency, with the current value standing at 17.55. The use of high-cost cryochambers guarantees the preservation of gene therapies. The absence of direct market peers allows the issuer to ignore price wars, focusing instead on the medical superiority of its products.

This indicator assesses business solvency via the sum of cash and accounts receivable, excluding illiquid inventories to determine the real capacity to instantaneously settle short-term liabilities. An analysis of the acid-test ratio reveals whether CRISPR Therapeutics AG (CRSP) possesses sufficient resources to pay for the services of contract research organizations, ensuring the seamless execution of trials without the risk of capital freezes.